Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,013,832
  • Shares Outstanding, K 108,539
  • Annual Sales, $ 16,072 M
  • Annual Income, $ 8,075 M
  • 60-Month Beta 0.25
  • Price/Sales 4.46
  • Price/Cash Flow 8.44
  • Price/Book 3.72
Trade REGN with:

Options Overview Details

View History
  • Implied Volatility 28.99% ( -0.24%)
  • Historical Volatility 29.48%
  • IV Percentile 32%
  • IV Rank 37.74%
  • IV High 38.14% on 01/25/22
  • IV Low 23.44% on 06/02/21
  • Put/Call Vol Ratio 0.69
  • Today's Volume 673
  • Volume Avg (30-Day) 703
  • Put/Call OI Ratio 1.30
  • Today's Open Interest 28,738
  • Open Int (30-Day) 34,740

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 9.90
  • Number of Estimates 6
  • High Estimate 11.10
  • Low Estimate 8.07
  • Prior Year 27.97
  • Growth Rate Est. (year over year) -64.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
597.76 +15.58%
on 05/09/22
699.63 -1.25%
on 05/25/22
+0.55 (+0.08%)
since 04/25/22
3-Month
597.76 +15.58%
on 05/09/22
747.42 -7.56%
on 04/08/22
+72.22 (+11.67%)
since 02/25/22
52-Week
492.13 +40.39%
on 05/27/21
747.42 -7.56%
on 04/08/22
+192.85 (+38.72%)
since 05/25/21

Most Recent Stories

More News
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

REGN : 690.88 (+0.71%)
ABBV : 151.96 (+1.91%)
LPTX : 1.1900 (+6.25%)
SWTX : 32.67 (-3.00%)
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

REGN : 690.88 (+0.71%)
SNY : 55.85 (-0.78%)
ETTX : 2.19 (unch)
INMB : 6.17 (+12.59%)
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

REGN : 690.88 (+0.71%)
SNY : 55.85 (-0.78%)
ALKS : 28.85 (+1.76%)
SESN : 0.5045 (-3.17%)
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.

REGN : 690.88 (+0.71%)
GERN : 1.2900 (+1.57%)
ALKS : 28.85 (+1.76%)
BAYRY : 17.0700 (+0.06%)
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

REGN : 690.88 (+0.71%)
SNY : 55.85 (-0.78%)
ALKS : 28.85 (+1.76%)
SESN : 0.5045 (-3.17%)
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM:...

CMPI : 10.49 (unch)
REGN : 690.88 (+0.71%)
The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical

Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog

REGN : 690.88 (+0.71%)
VRTX : 270.84 (+0.88%)
ICPT : 16.82 (+1.20%)
BHVN : 143.40 (+0.56%)
Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News

Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.

REGN : 690.88 (+0.71%)
VRTX : 270.84 (+0.88%)
ICPT : 16.82 (+1.20%)
BHVN : 143.40 (+0.56%)
Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?

The pharmaceutical company's COVID-19 treatment wasn't the only product suffering this past quarter.

REGN : 690.88 (+0.71%)
Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus

Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

REGN : 690.88 (+0.71%)
BAYRY : 17.0700 (+0.06%)
KOD : 6.68 (+2.45%)
FULC : 7.76 (-7.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 713.70
2nd Resistance Point 706.66
1st Resistance Point 698.77
Last Price 690.88
1st Support Level 683.85
2nd Support Level 676.81
3rd Support Level 668.92

See More

52-Week High 747.42
Last Price 690.88
Fibonacci 61.8% 649.90
Fibonacci 50% 619.78
Fibonacci 38.2% 589.65
52-Week Low 492.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar